Klee Justin B. 4

What Happened

• Justin B. Klee, CEO of Amylyx Pharmaceuticals (AMLX), was granted equity awards on 2026-03-05: 248,865 restricted stock units (RSUs) and a 373,295-share derivative award. Both grants were reported as acquisitions at $0.00 (no cash paid). These are compensation awards, not open-market purchases or sales.

Key Details

• Transaction date: March 5, 2026. Form 4 filed March 9, 2026 (within the 2 business-day filing window — timely).
• Reported amounts/prices: 248,865 shares @ $0.00 (RSU award); 373,295 shares @ $0.00 (derivative award).
• Shares owned after transaction: Not specified in the filing.
• Footnotes:
  • F1 (RSUs): The 248,865 RSUs vest in four equal annual installments, first vesting March 1, 2027, subject to continued service.
  • F2 (derivative): 25% of the derivative award vests and becomes exercisable on March 1, 2027; remaining shares vest monthly over the next 36 months, subject to continued service — indicating an option-like vesting schedule.
• No indication of tax withholding sale, 10b5-1 plan, or other special sale conditions in the filing.

Context

• These grants are standard executive compensation intended to retain and incentivize the CEO; they do not represent an immediate cash investment by the insider. Because the awards vest over time and are service-contingent, they do not signal an immediate market buy or sell by the CEO. For retail investors, such grants are routine but worth noting for future potential insider stock sales or exercise activity as vesting dates approach.